Premium
Soluble HLA Class I and Beta‐2‐Microglobulin Plasma Concentrations during Interferon Treatment of Chronic Myelogenous Leukemia
Author(s) -
Hillebrand Klaus,
Moritz Thomas,
Westhoff Ulrike,
Niederle Norbert,
GrosseWilde Hans
Publication year - 1994
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1994.tb01258.x
Subject(s) - beta 2 microglobulin , chronic myelogenous leukemia , medicine , gastroenterology , interferon , immunology , leukemia , chemotherapy
Soluble class I molecules (sHLA‐ABC) were measured by an enzyme‐linked immunosorbent assay (ELISA) in plasma samples of 13 patients with chronic‐phase Ph 1 ‐positive chronic myelogenous leukemia (CML). The patients were treated once daily with interferon (IFN) s.c. at a dosage of 4 times 10 6 IU/m 2 IFN‐α‐2b or in combination with 50 μg IFN‐γ. Measurements were performed before 2, 4, 6, 8, 24, 48, and 72 h after the start of treatment and thereafter every 2–4 weeks. Baseline sHLA‐ABC levels were within normal limits (mean 22.1+8.8 mg/l). An initial decrease of sHLA‐ABC (mean 3.2+2.7 mg/l) was seen in all patients during the first 2–8 h of IFN treatment. Thereafter, sHLA‐ABC levels increased steadily reaching maximum values within 2–5 weeks. The overall increase was 12.7+12.4 mg/l. During the following 2–4 months of IFN treatment sHLA‐ABC decreased to near baseline levels in 12 of 13 patients. No difference was detected between IFN‐α and IFN‐α plus IFN‐γ treatment. β 2 ‐Microglobulin values were measured in 8 patients and were found to be correlated to sHLA‐ABC concentrations (r = 0.48).